The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease
Empagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.
Authors
- Dorit Leshem‐Lev
- Roy Hershenson
- Ran Kornowski (ORCID: https://orcid.org/0000-0002-7708-8253)
- Alon Eisen (ORCID: https://orcid.org/0000-0003-0440-1648)
- Inbar Nardi Agmon (ORCID: https://orcid.org/0000-0001-7995-789X)
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1186/s12933-024-02466-x
- Citations
- 7
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.64